• +1-646-491-9876
    • +91-20-67278686

    Search

    Hypoglycemia Pipeline Review H2 2017

    Hypoglycemia Pipeline Review H2 2017

    • Report Code ID: RW0001884160
    • Category Pharmaceuticals
    • No. of Pages 80
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    Hypoglycemia - Pipeline Review, H2 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Hypoglycemia - Pipeline Review, H2 2017, provides an overview of the Hypoglycemia (Metabolic Disorders) pipeline landscape.

    Hypoglycemia is a condition characterized by an abnormally low level of blood sugar (glucose) . Symptoms of hypoglycemia include tachycardia, anxiety, shaking, and irritability, feelings of hunger, weakness, tiredness, dizziness, headache, confusion, and trouble concentrating. Risk factors include drug or alcohol consumption, older age, longer duration of diabetes, renal disease, peripheral neuropathy, obesity and cognitive dysfunction.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Hypoglycemia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Hypoglycemia (Metabolic Disorders) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Hypoglycemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypoglycemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 2, 6, 5, 3 and 2 respectively.

    Hypoglycemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Hypoglycemia (Metabolic Disorders) .
    - The pipeline guide reviews pipeline therapeutics for Hypoglycemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Hypoglycemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Hypoglycemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Hypoglycemia (Metabolic Disorders)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Hypoglycemia (Metabolic Disorders) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Hypoglycemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    List of Tables 4
    List of Figures 4
    Introduction 5
    Publisher Report Coverage 5
    Hypoglycemia - Overview 6
    Hypoglycemia - Therapeutics Development 7
    Pipeline Overview 7
    Pipeline by Companies 8
    Products under Development by Companies 10
    Hypoglycemia - Therapeutics Assessment 12
    Assessment by Target 12
    Assessment by Mechanism of Action 14
    Assessment by Route of Administration 16
    Assessment by Molecule Type 18
    Hypoglycemia - Companies Involved in Therapeutics Development 20
    Adocia SAS 20
    Arecor Ltd 20
    Eiger BioPharmaceuticals Inc 21
    Eli Lilly and Company 21
    Heptares Therapeutics Ltd 22
    LATITUDE Pharmaceuticals Inc 22
    Novartis AG 23
    Therakind Ltd 23
    USV Pvt Ltd 24
    Vectura Group Plc 24
    XERIS Pharmaceuticals Inc 25
    XOMA Corp 25
    Zealand Pharma AS 26
    Zucara Therapeutics Inc 26
    Hypoglycemia - Drug Profiles 27
    (glucagon + GLP-1) - Drug Profile 27
    (insulin human + pramlintide) - Drug Profile 28
    dasiglucagon - Drug Profile 29
    Drug for Hypoglycemia - Drug Profile 33
    exendin- (9-39) - Drug Profile 34
    glucagon - Drug Profile 37
    glucagon - Drug Profile 41
    glucagon - Drug Profile 42
    glucagon - Drug Profile 43
    glucagon biosimilar - Drug Profile 44
    LY-3143753 - Drug Profile 45
    LY-3185643 - Drug Profile 46
    LY-900018 - Drug Profile 47
    pasireotide - Drug Profile 49
    PRL-2903 - Drug Profile 53
    Recombinant Peptide 1 to Agonize Glucagon Receptor for Hypoglycemia - Drug Profile 54
    Recombinant Peptide to Agonize Glucagon Receptor for Hypoglycemia - Drug Profile 55
    Small Molecule to Antagonize GLP-1 Receptor Hypoglycemia and Congenital Hyperinsulinism - Drug Profile 56
    terbutaline sulphate MR - Drug Profile 57
    XOMA-129 - Drug Profile 58
    XOMA-358 - Drug Profile 59
    Hypoglycemia - Dormant Projects 62
    Hypoglycemia - Discontinued Products 63
    Hypoglycemia - Product Development Milestones 64
    Featured News & Press Releases 64
    Appendix 77
    Methodology 77
    Coverage 77
    Secondary Research 77
    Primary Research 77
    Expert Panel Validation 77
    Contact Us 77
    Disclaimer 78

    List of Tables

    Number of Products under Development for Hypoglycemia, H2 2017
    Number of Products under Development by Companies, H2 2017
    Products under Development by Companies, H2 2017
    Products under Development by Companies, H2 2017 (Contd..1) , H2 2017
    Number of Products by Stage and Target, H2 2017
    Number of Products by Stage and Mechanism of Action, H2 2017
    Number of Products by Stage and Route of Administration, H2 2017
    Number of Products by Stage and Molecule Type, H2 2017
    Hypoglycemia - Pipeline by Adocia SAS, H2 2017
    Hypoglycemia - Pipeline by Arecor Ltd, H2 2017
    Hypoglycemia - Pipeline by Eiger BioPharmaceuticals Inc, H2 2017
    Hypoglycemia - Pipeline by Eli Lilly and Company, H2 2017
    Hypoglycemia - Pipeline by Heptares Therapeutics Ltd, H2 2017
    Hypoglycemia - Pipeline by LATITUDE Pharmaceuticals Inc, H2 2017
    Hypoglycemia - Pipeline by Novartis AG, H2 2017
    Hypoglycemia - Pipeline by Therakind Ltd, H2 2017
    Hypoglycemia - Pipeline by USV Pvt Ltd, H2 2017
    Hypoglycemia - Pipeline by Vectura Group Plc, H2 2017
    Hypoglycemia - Pipeline by XERIS Pharmaceuticals Inc, H2 2017
    Hypoglycemia - Pipeline by XOMA Corp, H2 2017
    Hypoglycemia - Pipeline by Zealand Pharma AS, H2 2017
    Hypoglycemia - Pipeline by Zucara Therapeutics Inc, H2 2017
    Hypoglycemia - Dormant Projects, H2 2017
    Hypoglycemia - Discontinued Products, H2 2017

    List of Figures

    Number of Products under Development for Hypoglycemia, H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products by Top 10 Targets, H2 2017
    Number of Products by Stage and Top 10 Targets, H2 2017
    Number of Products by Top 10 Mechanism of Actions, H2 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
    Number of Products by Routes of Administration, H2 2017
    Number of Products by Stage and Routes of Administration, H2 2017
    Number of Products by Molecule Types, H2 2017
    Number of Products by Stage and Molecule Types, H2 2017
    Adocia SAS
    Arecor Ltd
    Eiger BioPharmaceuticals Inc
    Eli Lilly and Company
    Heptares Therapeutics Ltd
    LATITUDE Pharmaceuticals Inc
    Novartis AG
    Therakind Ltd
    USV Pvt Ltd
    Vectura Group Plc
    XERIS Pharmaceuticals Inc
    XOMA Corp
    Zealand Pharma AS
    Zucara Therapeutics Inc

    Request for Sample

    Report Url http://www.reportsweb.com//hypoglycemia-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//hypoglycemia-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//hypoglycemia-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments